Journal of VitreoRetinal Diseases最新文献

{"title":"Examination of Alzheimer Disease and Antidementia Medications' Effect on Age-Related Macular Degeneration.","authors":"Sonia B Kim, Hejin Jeong, David C Kaelber, Rishi P Singh, Katherine E Talcott","doi":"10.1177/24741264261490775","DOIUrl":"https://doi.org/10.1177/24741264261490775","url":null,"abstract":"<p><strong>Purpose: </strong>To clarify the prevalence of age-related macular degeneration (AMD) in Alzheimer disease and assess whether antidementia medications modify this relationship.</p><p><strong>Methods: </strong>A retrospective cohort study was performed using electronic health record data (TriNetX) of adults aged 65 years and older with 10 or more years of ophthalmology follow-up. Patients with Alzheimer disease were compared with controls to estimate unadjusted and propensity score-adjusted prevalence odds ratios (ORs) for any AMD and progression to advanced AMD. Within the Alzheimer disease cohort, associations between duration of exposure to antidementia medication and AMD were evaluated.</p><p><strong>Results: </strong>AMD prevalence was higher in patients with Alzheimer disease (n = 4257) compared with controls (n = 140 378) before (prevalence OR, 1.57; 95% CI, 1.46-1.69), but not after adjustment (adjusted prevalence OR, 1.03; 95% CI, 0.92-1.15). Advanced AMD prevalence was comparable between cohorts, and no association was found between exposure to antidementia medication and AMD risk.</p><p><strong>Conclusions: </strong>fter adjustment for confounders, Alzheimer disease and antidementia medications were not associated with AMD development or progression.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261490775"},"PeriodicalIF":1.3,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13677991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravitreal ONL1204 Ophthalmic Solution in Subjects With Macula-Off Rhegmatogenous Retinal Detachment.","authors":"David M Kleinman, Charles C Wykoff, Durga S Borkar, David R P Almeida, Allen C Ho, Joan W Miller, Andrew J Kocab, Lindsay Puscas, Stephanie C Wietholter, Lori L Kesteloot, David N Zacks","doi":"10.1177/24741264261495492","DOIUrl":"10.1177/24741264261495492","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the safety and efficacy of ONL1204 as an adjunct to standard-of-care surgical repair in subjects with macula-off rhegmatogenous retinal detachment (RRD).</p><p><strong>Methods: </strong>A phase 2, randomized, sham-controlled, single-masked, dose-ranging, multicenter trial was performd in which participants received either a single intravitreal injection of ONL1204 (50 μg or 200 μg) or a sham injection before surgical repair of RRD. The primary endpoint was the mean area under the log contrast sensitivity function at week 24 for participants who did not have primary surgical failure. Key secondary endpoints included mean area under the log contrast sensitivity function at week 12 and mean best-corrected visual acuity (BCVA) at weeks 12 and 24.</p><p><strong>Results: </strong>One hundred thirty-six enrolled patients were randomized to receive 50 μg ONL1204 (n = 46), 200 μg ONL1204 (n = 45), or sham (n = 45). The primary endpoint was not met; no significant differences were seen in area under the log contrast sensitivity function and BCVA across the groups at weeks 12 or 24. Post-hoc subgroup analyses revealed that higher proportions of pseudophakic patients (88.2% vs 50.0%; <i>P</i> = .013) and patients with >8 days of macular detachment (47.4% vs 10.0%; <i>P</i> = .098) treated with 200 μg ONL1204 achieved 20/50 or better vision at 24 weeks vs sham. ONL1204 demonstrated a favorable safety profile.</p><p><strong>Conclusions: </strong>ONL1204 was observed to be safe and well-tolerated. Although the primary endpoint was not met, the potential remains for visual acuity outcomes to be enhanced in patients at higher risk of vision loss from RRD, such as those with an extended duration of macula-off status.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261495492"},"PeriodicalIF":1.3,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13676687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Risk of Retinal Vascular Occlusions.","authors":"Nadia J Abbass, Kevin C Allan, David C Kaelber, Rishi P Singh, Katherine E Talcott, Aleksandra V Rachitskaya","doi":"10.1177/24741264261486777","DOIUrl":"https://doi.org/10.1177/24741264261486777","url":null,"abstract":"<p><p><b>Purpose:</b> To investigate whether glucagon-like peptide-1 receptor agonists are protective against retinal vascular occlusions. <b>Methods:</b> Using a large aggregated, de-identified electronic health records data platform in the United States, patients with type 2 diabetes ages ≥18 years prescribed glucagon-like peptide-1 receptor agonists or non-glucagon-like peptide-1 receptor agonists (controls) and having ophthalmology follow-up of at least 1, 3, or 5 years were included. The glucagon-like peptide-1 receptor agonist and control cohorts were propensity score matched (1:1) on demographics and risk factors, and outcomes were compared at 1, 3, and 5 years. Hazard ratios (HRs) with 95% CIs were reported, with significance defined as <i>P</i> < .05. <b>Results:</b> After matching, each cohort comprised 53 413 patients after 1 year, 25 738 patients after 3 years, and 14 695 patients after 5 years. Significantly reduced risk of all vascular occlusions was observed in the glucagon-like peptide-1 receptor agonist cohort at 1 year (HR, 0.66, 95% CI, 0.54-0.80), 3 years (HR, 0.71, 95% CI, 0.59-0.86), and 5 years (HR, 0.79, 95% CI, 0.64-0.97). Retinal vein occlusion risk was significantly reduced in the glucagon-like peptide-1 receptor agonist cohort up to 3 years (HR, 0.75, 95% CI, 0.60-0.94), but not after 5 years (HR, 0.83, 95% CI, 0.64-1.08). While there was no reduction in retinal artery occlusion risk at 1 year (HR, 0.69, 95% CI, 0.48-1.00), there were significant reductions at later time points. <b>Conclusions:</b> Results suggest that glucagon-like peptide-1 receptor agonists may reduce the risk of retinal vascular occlusions. Additional prospective trials and analysis of long-term outcomes are needed to further investigate this association.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261486777"},"PeriodicalIF":1.3,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13677990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structural and Vascular Findings in Autologous Retinal Transplantation for Macular Hole.","authors":"Jad Madani, Rami Madani, Timothy Mayotte, Ahmad Zeido, Tarek Alasil","doi":"10.1177/24741264261495475","DOIUrl":"10.1177/24741264261495475","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the fluorescein angiography (FA) and optical coherence tomography angiography (OCTA) findings in autologous retinal transplantation for refractory full-thickness macular hole (FTMH).</p><p><strong>Methods: </strong>A single case was reviewed.</p><p><strong>Results: </strong>A 71-year-old Hispanic man presented with a refractory FTMH for which internal limiting membrane peel and gas tamponade had previously failed. The axial length was 23.17 mm, and the basal diameter measured 1500 µm (corrected to 1448.13 µm). The patient underwent pars plana vitrectomy and autologous retinal transplantation with short-term perfluoro-n-octane heavy liquid, followed by gas tamponade. The patient was followed for 4 years (48 months). Complete anatomic closure of the FTMH was seen on OCT. The preoperative best-corrected Snellen visual acuity was counting fingers, which improved to 20/100 at 13 months postoperatively. FA showed intragraft vascularization, and evidence of reperfusion at the superficial plexus level was seen on OCTA.</p><p><strong>Conclusions: </strong>Autologous retinal transplantation for this large, refractory FTMH provided anatomic closure with vascularization of the graft and improvement in visual acuity.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261495475"},"PeriodicalIF":1.3,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13672706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Versus Centers for Medicare and Medicaid Services Estimates of Pediatric Retinal Detachment Repair Times.","authors":"Ella H Leung, Hong-Uyen Hua, Nita Valikodath, Yoshihiro Yonekawa, Victor M Villegas, Audina Berrocal, Mary Elizabeth Hartnett, Prethy Rao, Emmanuel Y Chang, Robert A Sisk, Edward H Wood, Clio Armitage Harper, Celine Chaaya, Salma Fleifil, Tadashi Yokoi, Roselind Ni, Joaquín Sosa-Lockward, Melissa Yuan, Neal Shah, Ravneet S Rai, Vy Lieu, Ghassan Ghorayeb, Geoffrey G Emerson, Jill Blim, Nimesh A Patel","doi":"10.1177/24741264261490790","DOIUrl":"10.1177/24741264261490790","url":null,"abstract":"<p><strong>Purpose: </strong>To compare real-world pediatric retinal detachment (RD) repair times with the Centers for Medicare and Medicaid Services (CMS) estimates for complex RD surgeries.</p><p><strong>Methods: </strong>A cross-sectional survey was performed of complex pediatric RD perioperative times from pediatric retina specialists across the United States.</p><p><strong>Results: </strong>A total of 152 patients were included. The mean (±SD) age at the initial visit was 9.2 ± 5.8 years, and the mean (±SD) follow-up was 2.31 ± 1.95 years. The most common complex pediatric RD surgeries were pars plana vitrectomy (PPV) (61%, n = 92), followed by combined scleral buckle (SB)/PPV (21%, n = 32) and SBs (20%, n = 30). Surgeries were most commonly performed at hospitals (66%, n = 104), which were associated with longer intraoperative times than in ambulatory surgery centers (median, 150 minutes vs 121 minutes; <i>P</i> = .004). The most common medical insurance was Medicaid (49%). There was a median of 135 minutes (interquartile range [IQR], 74-200 minutes) of uncompensated physician time for patient phone calls, contacting insurances, and surgery turnover for each patient. Combined preoperative pediatric surgery times were longer in the real-world survey than CMS estimates (median, 92 minutes [IQR, 67.5-120 minutes] vs 63.5 minutes [IQR, 51.5-64 minutes]; <i>P</i> < .001). Real-world intraoperative times were also higher than CMS estimates (median, 141 minutes [IQR, 110-192 minutes] vs 133 minutes [IQR, 120-138 minutes]; <i>P</i> = .003). Approximately 38% of patients needed another surgery postoperatively, most commonly another RD repair (63%).</p><p><strong>Conclusions: </strong>Pediatric RD repairs may be undervalued by CMS estimates. The intraoperative times were longer, and physicians spent an extra 2.25 hours of uncompensated time caring for each child in the perioperative period. The current reimbursements may not fully account for the complexity and length of perioperative care for pediatric RDs.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261490790"},"PeriodicalIF":1.3,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Follow-Up of Macular Telangiectasis Type 2-Like Maculopathy in Hereditary Sensory and Autonomic Neuropathy Type 1.","authors":"Ogul E Uner, Kaiyo Shi, Ronald P Davis, Aristomenis Thanos","doi":"10.1177/24741264261496254","DOIUrl":"10.1177/24741264261496254","url":null,"abstract":"<p><strong>Purpose: </strong>To report the long-term follow-up of macular telangiectasia type 2-like disease in a patient with hereditary sensory and autonomic neuropathy 1.</p><p><strong>Methods: </strong>A single case was reviewed over 15 years.</p><p><strong>Results: </strong>A 48-year-old White woman with chronic peripheral neuropathy and fractures presented with worsening blurry vision. Best-corrected visual acuity (BCVA) was 20/70 OD and 20/25 OS. Initial examination showed bilateral subfoveal retinal cavitation and pseudovitelliform lesions, with cone dysfunction on multifocal electroretinography. Genetic testing demonstrated a serine palmitoyl transferase mutation consistent with hereditary sensory and autonomic neuropathy 1. Over 15 years, bilateral full-thickness macular holes, retinal pigmentary changes, and outer retinal veno-venous anastomoses developed. BCVA was 20/70 OU. Bilateral vitrectomy with inverted internal limiting membrane flaps improved BCVA to 20/60 OD and 20/50 OS.</p><p><strong>Conclusions: </strong>Hereditary sensory and autonomic neuropathy 1 can cause macular telangiectasia type 2-like maculopathy with atypical features but a long-term course similar to that of sporadic macular telangiectasia type 2, including macular hole formation. Genetic testing for hereditary sensory and autonomic neuropathy 1 should be considered when early peripheral neuropathy precedes macular disease.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261496254"},"PeriodicalIF":1.3,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative Analysis of Fibrovascular Membrane Traction in Antivascular Endothelial Growth Factor-Associated Crunch Syndrome Using Integrated Ultrawide-Field Imaging and Swept-Source Optical Coherence Tomography.","authors":"Yafeng Li, Assel Talaspayeva, Samet Gulkas, Mohamed Ashraf","doi":"10.1177/24741264261490794","DOIUrl":"10.1177/24741264261490794","url":null,"abstract":"<p><strong>Purpose: </strong>To characterize changes in fibrovascular membrane traction following antivascular endothelial growth factor (anti-VEGF) treatment in eyes with proliferative diabetic retinopathy.</p><p><strong>Methods: </strong>Fibrovascular membrane traction was decomposed into anteroposterior, tangential, and bridging vectors and quantitatively assessed using standardized ultrawide-field fundus imaging with navigated swept-source optical coherence tomography (OCT).</p><p><strong>Results: </strong>Five eyes of 5 patients with high-risk proliferative diabetic retinopathy demonstrated progression of fibrovascular membrane traction following intravitreal anti-VEGF injection. Ultrawide-field fundus imaging with navigated swept-source OCT showed increases in anteroposterior traction ranging from 5.3% to 62% and in tangential traction ranging from 3% to 14% compared with pre-injection measurements (follow-up interval, 1-10 weeks). Over a 6-month follow-up period, fibrovascular membrane traction remained stable in 4 eyes, whereas 1 eye developed macula-threatening traction and vision loss requiring vitrectomy.</p><p><strong>Conclusions: </strong>This retrospective series demonstrates dynamic changes in fibrovascular membrane traction following anti-VEGF therapy in proliferative diabetic retinopathy. Quantitative assessment using integrated ultra-widefield imaging and navigated swept-source OCT may provide a useful approach for monitoring tractional changes and informing clinical decision-making regarding fibrovascular membrane management. Larger prospective studies are warranted to validate these findings.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261490794"},"PeriodicalIF":1.3,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exudative Vitreoretinopathy and Vasoproliferative Retinal Lesion in <i>CTNNB1</i> Syndrome.","authors":"Louis K Aghanwa, Aliaa Abdelhakim, Brian Marr, Gaetano R Barile","doi":"10.1177/24741264261491129","DOIUrl":"https://doi.org/10.1177/24741264261491129","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the presentation, management, and genetic diagnosis of a young adult with <i>CTNNB1</i>-associated vitreoretinopathy and a vasoproliferative retinal tumor.</p><p><strong>Methods: </strong>A single case was evaluated.</p><p><strong>Results: </strong>A 22-year-old woman presented with progressive tractional changes in the left eye due to a peripheral vasoproliferative retinal tumor and exudative retinal detachment. She underwent primary vitrectomy with membrane peeling, endolaser, cryotherapy, and intravitreal antivascular endothelial growth factor, followed by vitrectomy and scleral buckling for recurrent detachment. Additional findings included contralateral chorioretinal coloboma and high refractive error. Retinal reattachment and vasoproliferative retinal tumor involution were achieved with surgery. Fluorescein angiography revealed peripheral avascularity in the right eye and leakage from the vasoproliferative retinal tumor in the left. Exome sequencing identified a heterozygous de novo <i>CTNNB1</i> variant, consistent with <i>CTNNB1</i>-associated syndrome. This case expands the known ophthalmic phenotype to include secondary vasoproliferative retinal tumor complicating <i>CTNNB1</i>-associated vitreoretinopathy.</p><p><strong>Conclusions: </strong>Discrete vasoproliferative retinal tumor and chorioretinal coloboma represent underrecognized features of <i>CTNNB1</i>-related vitreoretinopathy. Early recognition, surgical intervention, and genetic testing are critical in young patients with atypical vitreoretinal disease.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261491129"},"PeriodicalIF":1.3,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Retinal Necrosis in an Infant With Corneal and Macular Scarring: Other Considerations-Commentary.","authors":"Moustafa S Magliyah, Srinivasan Sanjay","doi":"10.1177/24741264261495457","DOIUrl":"https://doi.org/10.1177/24741264261495457","url":null,"abstract":"","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261495457"},"PeriodicalIF":1.3,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149168108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retinal Vasoproliferative Tumors in Real-World Practice.","authors":"Piero Barrera-Arshavin, Juan Cristóbal Ormeño-Illanes, Camilo Urzúa-Álvarez, Marcelo Azócar-Barrera, Bruno Caselli-Morgado, Alfredo Rojas-Torres, Álvaro Bofill Ramírez, José Manuel López-Astaburuaga, Sergio Zacharías-Santamaría, Efraín Pérez Argandoña, Jorge Orellana-Ríos, Luis Filsecker-López, Juan Ignacio Verdaguer-Díaz","doi":"10.1177/24741264261484834","DOIUrl":"https://doi.org/10.1177/24741264261484834","url":null,"abstract":"<p><p><b>Purpose:</b> To describe the clinical, anatomic, functional, and therapeutic characteristics of patients with retinal vasoproliferative tumors in real-world clinical practice, comparing the clinical features of primary and secondary tumors. <b>Methods:</b> A multicenter, retrospective, longitudinal case series study was conducted, including cases of retinal vasoproliferative tumors at 3 ophthalmology referral centers in Chile between 2006 and 2026. A total of 24 eyes from 23 patients with a clinical diagnosis of retinal vasoproliferative tumor were included. Demographic, topographic, biometric, functional, and treatment variables were analyzed. Parametric and nonparametric tests were used. <b>Results:</b> The mean age was 45.6 ± 15.2 years; 70.8% were primary tumors, and 29.2% were secondary. Most cases were unilateral (91.7%) and active at diagnosis (79.2%), with a predominance in the inferior and inferotemporal quadrants. The mean baseline best-corrected visual acuity was 0.75 ± 0.64 logMAR, and the final best-corrected visual acuity was 0.60 ± 0.79 logMAR, with no statistically significant overall functional improvement (<i>P</i> = .27). Laser photocoagulation, the most performed treatment, was done in 54.2%. A favorable anatomic response was achieved in 91.7% of eyes. Retreatment was more frequent in secondary than in primary tumors (85.7% vs 35.3%; absolute risk difference, +50.4%; odds ratio, 11.0; 95% CI, 1.06-114.1; Fisher exact <i>P</i> = .069). <b>Conclusions:</b> Retinal vasoproliferative tumors achieved a high rate of anatomic control with currently used therapies; however, functional recovery was limited. Secondary tumors showed a clinically important but statistically imprecise trend toward greater retreatment need; this finding should be regarded as hypothesis-generating and warrants close follow-up.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264261484834"},"PeriodicalIF":1.3,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13627463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}